Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
04. Januar 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition
13. Dezember 2021 09:00 ET
|
Annexon Biosciences
BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
09. November 2021 16:01 ET
|
Annexon Biosciences
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer
04. Oktober 2021 06:30 ET
|
Annexon Biosciences
– Dr. Ted Yednock’s appointment enhances Annexon’s commitment to scientific innovation and pursuit of future programs – – Dr. Larry Mattheakis brings decades of drug discovery and development...
Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
23. September 2021 06:30 ET
|
Annexon Biosciences
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
20. September 2021 06:30 ET
|
Annexon Biosciences
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
16. August 2021 16:01 ET
|
Annexon Biosciences
– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases – – Continued progress in...
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases
22. Juli 2021 07:00 ET
|
Annexon Biosciences
Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis Deepening ANX005 neuromuscular autoimmune pipeline with new Phase 2 program in Multifocal Motor Neuropathy ...
Annexon to Present at the Raymond James Human Health Innovation Conference
16. Juni 2021 07:00 ET
|
Annexon Biosciences
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies...
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results
17. Mai 2021 16:05 ET
|
Annexon Biosciences
– ANX005 Huntington’s Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 – – ANX009 First-in-Human dose-ranging trial completed with data expected summer 2021 – – Next generation...